HistoSonics, Inc.’s Post

HistoSonics, Inc. is excited to announce the first patients have been treated as part of our feasibility study, named the GANNON trial, designed to evaluate the safety of the Edison System and histotripsy to non-invasively destroy inoperable pancreatic tumors. #FirstEver #Histotripsy #HistoSonics

Reducing morbidity related to elective colorectal cancer surgery is essential for achieving comparable oncological outcomes in the octogenarian population. Great work by Ilze Ose from Center for Surgical Science (CSS) putting emphasis on tailored preoperative optimization approach for this patient group. A lot can be gained in the future for this patient group. VELUX FONDEN https://lnkd.in/dv7McJi6

🚨 Excited to share that our UroCCR - National network on Kidney Cancer NEPRAH study is published in European Urology Oncology! Alexandre Ingels 29 🇫🇷 French centers 3451 Patients included Objective: to evaluate perioperative, oncological, and functional outcomes of RAPN for hilar renal tumors compared to nonhilar tumors. 📊 Also included a subgroup analysis of 652 clampless RAPN Results 👇 Hilar RAPN compared to non-hilar RAPN: ⬆ Longer WIT ⬆Longer operative time ⬆More postoperative complications ↔ Similar blood loss and perioperative transfusion rate ↔ Similar postoperative eGFR change ↔ Comparable Trifecta achievement rates 🚫 No significant difference in RFS, CSS or OS (mean F-U: 31.9 mo) ↔ Comparable outcomes between clampless RAPN for hilar vs non hilar ▶ The hilar location of renal tumour should not be the only argument to perform radical or open surgery. 🎯 Think Contact Surface Area, tumour size and patients characteristics. A big thank you to all the co-authors and uroCCR patients for their invaluable contributions! Association Francaise Urologie Henri Mondor Hospital Greater Paris University Hospitals - AP-HP https://lnkd.in/e8vCZZkA

While today medical oncologists can build complex and more #PersonalisedTreatment strategies for #mCRC by integrating sequential chemotherapies, surgery, targeted agents and local treatments across multiple lines of therapy, patient selection is imperative to ensure good outcomes. Patient expectations and preferences must not be neglected when it comes to treatment. While novel agents continue to enrich the therapeutic armamentarium in this setting, patients expect not only longer survival times, but also better quality of life. #ESMOGI24  Read the interview with Eric Van Cutsem and Zorana Maravic about extending the continuum of care for metastatic colorectal cancer on #ESMODailyReporter  📌 https://lnkd.in/d2VpfWey

📃Scientific paper: Real-world outcomes of patients with renal cell carcinoma, surgically treated at regional hospitals, based on a prospective long-term survey of the pre-robotic era Abstract: Purpose Renal cancer surgery is frequently performed in small regional hospitals in Japan. This study evaluated the outcomes of renal cancer surgery, comparing results from the pre-robotic surgery era with those obtained with robotic surgery. Methods This prospective cohort study was conducted on patients who underwent renal cancer surgery between 2008 and 2013 at 14 hospitals, comprising 13 regional hospitals and a university hospital, registered in the Tohoku Urological Evidence-Based Medicine Study Group. The patients’ backgrounds; perioperative data; annual postoperative renal function; and prognostic surveys, performed over a median follow-up period of 10 years were obtained. Results In 930 surgical cases at the 14 registered hospitals, the 10-year recurrence-free survival rates of cT1a, cT1b, cT2, and cT3 were 0.9326, 0.8501, 0.5786, and 0.5101, respectively. Meanwhile, the 10-year overall survival rates were 0.9612, 0.8662, 0.7505, and 0.7209, respectively. Long-term observation in patients with cT1 showed that vessel involvement and high tumor grade were prognostic factors for recurrence. As a noteworthy fact, radical nephrectomy was performed in 53.3% of patients with cT1a at the regional hospitals. However, even in patients with preoperative chronic kidney disease stage 3, radical nephrectomy was not a prognostic factor of renal function. This indicates that compensatory mechanisms had been working for a long time in many patients who underwent radical ne... Continued on ES/IODE ➡️ https://etcse.fr/1MS ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

I’m very glad to anounce that the November printed issue of The Journal of Thoracic and Cardiovascular Surgery (#JTCVS) includes our article titled Video-assisted mediastinoscopic lymphadenectomy (VAMLA): mature results for staging non-small cell lung cancer with normal mediastinum. Exciting results regarding: 1) The accuracy of this technique to detect unsuspected N2-3 in patients with tumours with normal medistinum. 2) The impressive rate of unsuspected N2-3 (specially in cN1) 3)The role of VAMLA in those patients with left-side tumors as a pre-resection lymphadenectomy

𝗔𝘅𝗶𝗹𝗹𝗮𝗿𝘆 𝗗𝗶𝘀𝘀𝗲𝗰𝘁𝗶𝗼𝗻 𝘃𝘀. 𝗔𝘅𝗶𝗹𝗹𝗮𝗿𝘆 𝗥𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗔𝗳𝘁𝗲𝗿 𝗡𝗔𝗖𝗧 𝗶𝗻 𝗟𝗼𝘄-𝗕𝘂𝗿𝗱𝗲𝗻 𝗡𝗼𝗱𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲: 𝗔𝗿𝗲 𝘁𝗵𝗲 𝗢𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗖𝗼𝗺𝗽𝗮𝗿𝗮𝗯𝗹𝗲? 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 The surgical management of breast cancer is increasingly shifting towards less invasive techniques, such as sentinel lymph node biopsy (SLNB), in an effort to reduce complications like lymphedema. Traditionally, axillary lymph node dissection (ALND) has been the standard of care for patients with chemoresidual nodal disease (ypN-positive[sn]) following neoadjuvant therapy (NACT), primarily due to the higher risk of residual disease associated with SLNB alone. However, the efficacy of adjuvant radiation therapy (RT) in managing residual nodal disease without the necessity of ALND remains under investigation. While the Alliance A011202 trial is anticipated to provide definitive evidence, this study aims to determine whether SLNB followed by RT could yield outcomes comparable to ALND in patients with ypN-positive disease. 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 - 𝗠𝗲𝗱𝗶𝗮𝗻 𝗙𝗼𝗹𝗹𝗼𝘄-𝘂𝗽: 4.5 years (range 0.5-7.1 years) - 𝗡𝘂𝗺𝗯𝗲𝗿 𝗼𝗳 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀: 630 (599 received ALND, 31 received SLNB) - 𝗟𝗥𝗥, 𝗗𝗠, 𝗢𝗦, 𝗕𝗖𝗦𝗦, 𝗮𝗻𝗱 𝗗𝗙𝗦: No significant differences were observed between the SLNB and ALND groups in terms of local-regional recurrence (LRR), distant metastasis (DM), overall survival (OS), breast cancer-specific survival (BCSS), or disease-free survival (DFS). Both groups had high rates of adjuvant RT, and among the subset who received regional nodal irradiation (RNI), outcomes were similar regardless of the surgical approach. 𝗖𝗼𝗻𝗰𝗹𝘂𝘀𝗶𝗼𝗻 This analysis suggests that SLNB, when followed by RT, may offer outcomes comparable to ALND in the management of ypN-positive breast cancer, despite the traditionally perceived higher risk associated with SLNB. These findings support the potential for less invasive surgical approaches in selected patient populations. However, the small sample size and lack of detailed data on nodal burden and RT specifics limit the ability to draw definitive conclusions. Further results from the ongoing Alliance trial are eagerly awaited to provide clearer guidance and potentially influence future standards of care. #radiationoncology #radonc #radiotherapy #oncology #breast #breastcancer https://lnkd.in/em4NBurz

🚨 New Research Alert: Removing Appendix Could Lower Risk of Certain Colorectal Cancer 🚨 📌 The appendix, once thought to be a useless organ, has shown its importance in the immune system. But what happens to our health when it's removed? 📌 Researchers at Brigham and Women's Hospital have uncovered a fascinating link: undergoing an appendectomy could reduce the risk of developing a specific subtype of colorectal cancer associated with the tumor-promoting bacteria Fusobacterium nucleatum. This groundbreaking study, published in the Annals of Surgery, highlights the potential long-term health impacts of appendectomy. 🔖 Read more at https://lnkd.in/d7dSPxpd. #HealthResearch #ColorectalCancer #GutHealth #Appendectomy #MedicalResearch #BrighamAndWomensHospital #Microbiome #CancerPrevention

Findings from an updated analysis of the CIRCULATE-Japan GALAXY study strongly validates previous finding that observation alone may be sufficient for favourable outcomes among molecular residual disease negative colorectal cancer patients, whereas molecular residual disease positive patients derive significant benefit from adjuvant chemotherapy. Although T4N0 demonstrated slightly inferior outcomes compared to the T3N0 counterparts, adjuvant chemotherapy did not show any survival benefit after adjusting for age, sex and performance status to mitigate residual bias. This finding provides further support for the randomised, phase III VEGA study in the CIRCULATE-Japan platform, which is currently assessing the non-inferiority of observation alone compared to standard adjuvant chemotherapy in patients with high-risk stage II or low-risk pathological stage III CRC who are confirmed to be ctDNA negative 4 weeks after surgery. #colorectalcancer #circulatingDNAcoloncancer

In this phase II study, 47 patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) received three cycles of pembrolizumab plus chemotherapy, followed by Da Vinci robot-assisted surgery. The primary endpoints were safety and major pathological response (MPR). Key secondary endpoints included complete pathological response (pCR) and survival. No grade ≥3 adverse events or surgical delays occurred during neoadjuvant therapy. Among 46 patients studied for efficacy, the MPR and pCR rates were 72% and 41%, respectively. After a median follow-up of 27.2 months, the 2-year overall survival (OS) and disease-free survival (DFS) rates were 91% and 89%, respectively. Expansion of TRGC2+ NKT cells in peripheral blood correlated with neoadjuvant treatment effectiveness, which was validated by in vitro organoid experiments and external cancer datasets, and its functional classification and mechanism of action were further explored. These findings show preoperative pembrolizumab plus chemotherapy is a promising therapeutic strategy for resectable ESCC. New publication on the Keystone-001 trial investigating the efficacy of preoperative pembrolizumab plus chemotherapy in resectable esophageal squamous cell carcinoma (ESCC). The text above is from the author's abstract, the full paper can be found here: https://lnkd.in/eAJHEVJB